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Abstract
Antisense oligonucleotides are an emerging therapeutic option to treat diseases with known genetic origin. In the
age of personalised medicines, antisense oligonucleotides can sometimes be designed to target and bypass or
overcome a patient’s genetic mutation, in particular those lesions that compromise normal pre-mRNA processing.
Antisense oligonucleotides can alter gene expression through a variety of mechanisms as determined by the
chemistry and antisense oligomer design. Through targeting the pre-mRNA, antisense oligonucleotides can alter
splicing and induce a specific spliceoform or disrupt the reading frame, target an RNA transcript for degradation
through RNaseH activation, block ribosome initiation of protein translation or disrupt miRNA function. The recent
accelerated approval of eteplirsen (renamed Exondys 51™) by the Food and Drug Administration, for the treatment
of Duchenne muscular dystrophy, and nusinersen, for the treatment of spinal muscular atrophy, herald a new and
exciting era in splice-switching antisense oligonucleotide applications to treat inherited diseases. This review considers
the potential of antisense oligonucleotides to treat inherited lung diseases of childhood with a focus on cystic fibrosis
and disorders of surfactant protein metabolism.
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Introduction
Antisense oligonucleotides (AOs) have the ability to
modulate gene expression by interacting with specific
gene transcripts through a variety of mechanisms.
Decades ago, ambitious claims were made regarding the
potential of AO technology to modulate gene expression
in the treatment of human disease, but with most new
drug discovery platforms, various factors including
inconsistent synthesis protocols, inadequate understand-
ing of mechanisms and limited experimental controls
have hindered the technology’s progress. Only a handful
of AOs have been approved for clinical use to date,
despite years of clinical development, and in hindsight, it
is remarkable that each approved treatment invokes a
different mechanism of action [1].
Recently, two new drugs have been approved to
treat two “common” rare and severe genetic diseases:
Duchenne muscular dystrophy (DMD) [2] and spinal
muscular atrophy (SMA) [3]. In both these cases, the
intervention is designed to redirect pre-mRNA pro-
cessing, in the case of DMD, through induction of
targeted exon skipping, while in SMA, the aim is to
promote exon retention to produce a functional tran-
script. All human genes undergo some form of pre-
mRNA processing during expression and the majority
of primary gene transcripts undergo either constitu-
tive or alternative splicing, where noncoding intronic
sequences are removed from the mature mRNA and
exons are precisely spliced together. Mutations that
cause abnormal splicing, complete or partial exon loss
or the retention of intronic sequences, are now recog-
nised as being relatively common causes of human
disease [4]. Hence, the potential for AO modification
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of gene expression as a therapeutic strategy is
currently being explored in other disease settings.
Vigorous research is focussing on refining AO chemis-
tries and modifications to improve bioavailability, safety,
potency and reduction of off-target effects [5–7]. How-
ever, challenges facing the clinical translation of this
technology still exist, particularly with respect to effi-
cient delivery and nuclear uptake of AO in target tissues,
and will vary depending upon the target tissue and
disease. In addition, clinical trial design and evaluation
of novel therapeutics in conditions where the patient
population is small and disease progression is slow will
most likely demand innovative and adaptive trials [8–11].
In this review, we provide an introductory overview of AO
chemistries, mechanisms and the advantages of each with
particular attention to the potential to treat respiratory
diseases of genetic origin.
Review
Antisense oligonucleotide chemistry
Antisense oligonucleotides are short, single strands of
nucleic acid, commonly cited to be 13–50 nucleotides
long but in practise are more typically 20–25 bases in
length. Appropriately designed compounds can bind
with high affinity and specificity to given nucleic acid
targets through Watson and Crick base-pairing [12]. As
the natural phosphodiester backbone of RNA and DNA
is particularly susceptible to nuclease degradation, the
chemistry used for each nucleotide in early studies that
used AOs was unstable and generally ineffective. This
limitation was quickly recognised, and chemical modifi-
cations to the oligonucleotide backbone were made,
aiming to improve target affinity, nuclease resistance,
toxicology profile, biostability and pharmacokinetics
[13–21]. To date, a wide variety of AO analogues have
been generated that vary in their pharmacological
properties, and these further contribute to the mecha-
nisms of action [5]. The chemistry of particular AO ana-
logues have been reviewed in depth elsewhere [15–17]
and will not be discussed in detail in this review. Proper-
ties of commonly used nucleotide chemistries that are
used to formulate AOs are summarised in Table 1.
As mentioned above, AOs can modulate gene expres-
sion through a variety of mechanisms depending on the
base modification, backbone and sequence design. Some
AO chemistries activate RNase H, a ubiquitous ribo-
nuclease, which specifically hydrolyses the phospho-
diester bonds of the RNA strand in DNA to RNA
hybrids, thereby degrading the RNA transcript and
preventing translation of the encoded protein. RNase H
activity is supported by DNA-like AO chemistries on a
phosphorothioate backbone [18]. Although the inclusion
of the phosphorothioate backbone does confer some
increased nuclease resistance to the AOs, these com-
pounds have a limited biological half-life of around 35 to
50 h [19]. Extended AO stability and hence activity has
been achieved through the incorporation of modified
bases, such as LNA, 2′-O-methyl and 2′-O-methoxyethyl
modifications at the 5′ and 3′ ends of the oligomer to
make a “gapmer” [5]. Other AO-induced mechanisms of
gene downregulation may involve the steric inhibition of
ribosomal complex formation by preventing translation
initiation, modulating the pre-mRNA splicing process to
disrupt the reading frame or by removing exons encoding
crucial functional domains [20]. 2′-O-methyl- or 2′-O-
methoxyethyl-modified oligonucleotides, peptide nucleic
acids (PNAs) and phosphorodiamidate morpholino oligo-
mers (PMOs) do not support RNase H induction and are
also potential steric blocking compounds.
More than 95% of human genes consist of introns and
exons and must undergo splicing during pre-mRNA
maturation. At least 75% of our genes undergo some
degree of alternative splicing to generate multiple
isoforms from one gene. Hence, it is possible that the
application of AOs to treat a wide variety of human gene
mutations lies in therapeutic alternative splicing.
Through re-directing the normal pre-mRNA splicing
process, AOs could potentially generate non-functional
transcripts by targeted excision of a frameshifting exon
that would then render the induced transcript suscep-
tible to degradation through the nonsense-mediated
decay pathway [21]. Where some splice mutations result
in non-functional or deleterious protein isoforms, AOs
could be targeted to mutated splice motifs, thereby
modulating the splicing process and restoring the
Table 1 Common nucleotide chemistries used to synthesise antisense oligonucleotide molecule
Nucleotide chemistry Abbreviation Resistant to nuclease
degradation
RNase H
activation
Splice modulation Toxicity Charge Reference
Phosphorothioate DNA PS + + – ++ Negative [15]
2′-O-methyl RNA OMe + – + + Negative [16]
2′-O-Methoxyethyl RNA MOE + – + – Negative [13, 17]
Locked nucleic acid LNA + – + + Uncharged [14, 18, 19]
Phosphoroamidate morpholino PMO + – + – Uncharged [20]
Peptide nucleic acid PNA + – + – Uncharged [21]
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expression of functional protein. While intra-exonic and
intronic mutations that affect splicing enhancers could
potentially be targeted by AOs, intronic mutations that
involve the invariant bases flanking exons are unlikely to
be amenable to AO therapy. Splice-switching antisense
oligomers can also restore the function of a disease-
causing allele by altering a splice site or exon selection
to restore the open reading frame, compromised by a
disease-causing mutation.
Use of antisense therapy in disease
In 1978, Stephenson and Zamecnik showed that a 13-mer
oligodeoxyribonucleotide could inhibit Rous sarcoma virus
in cell cultures [22], and RNase H site-specific cleavage was
described soon after [23] (Fig. 1). However, it was not until
1998 that the first approved use of AOs occurred, when the
Food and Drug Administration permitted the commercial-
isation of fomivirsen (Vitravene) for the treatment of cyto-
megalovirus retinitis in AIDS patients [24]. Fomivirsen is a
21-mer phosphorothioate oligodeoxyribonucleotide that is
complementary to a portion of the human cytomegalovirus
(HCMV) gene and inhibits HCMV replication through an
antisense mechanism. However, due to the improvement in
other HIV/AIDS medications leading to the decline in
HIV-associated opportunistic CMV infections at the time,
Fomivirsen was voluntarily withdrawn from the market in
2002 [25]. The next FDA-approved use of antisense
oligonucleotides was Macugen (pegatanib). Macugen is a
single-stranded nucleic acid aptamer that binds to the
heparin-binding domain of vascular endothelial growth
factor (VEGF)-165 with extremely high affinity [26]. VEGF
is involved in pathologic angiogenesis; in particular, VEGF-
165 promotes angiogenesis in the eyes of patients with age-
related macular degeneration. In 2004, Macugen was ap-
proved as a treatment for age-related macular degeneration.
In 2013, mipomersen (KYNAMRO®) was approved by the
FDA for the management of homozygous familial hyper-
cholesterolemia, a genetic disorder characterised by high
cholesterol [27]. Mipomersen is an oligonucleotide inhibiter
of Apolipoprotein (Apo) B-100 synthesis. The AO sequence
is complementary to the Apo B-100 messenger RNA and,
when bound, activates RNase-H enzymatic cleavage of the
mRNA, thereby inhibiting translation of the gene product
and reducing circulating low-density lipoproteins that con-
tribute to familial hypercholesterolemia disease [27].
The above examples use AOs to alter gene expression,
either directly or via competitive binding to receptors, to
change disease progression. Another precise method to
alter disease progression is to manipulate splicing of
exons within a gene transcript using splice-switching
AOs. The first reported example of AO-mediated splice-
switching was reported by Dominski and Kole in 1993
who used AOs to correct abnormal splicing of a β-globin
transcript responsible for beta-thalassemia. This was
originally done in vitro with vector constructs and cell-
free extracts [28] and later in peripheral blood cells [29]
but has not yet proceeded to clinical trials. Therapeutic
interventions that exploit alternative splicing are also
being examined in diseases such as angioplasty restenosis
[30], cancer [31, 32], amyotrophic lateral sclerosis [7, 33]
and Huntington’s disease [34].
DMD is an X-linked recessive muscle-wasting disease
caused by mutations in the DMD gene that lead to
premature termination of translation [35]. A milder form
of disease, Becker muscular dystrophy (BMD), is generally
caused by in-frame deletions in the dystrophin gene that
lead to an internally truncated dystrophin protein that
retains partial function. The rationale behind splice-
switching therapy for DMD is to redirect dystrophin pre-
mRNA processing and induce a BMD-like dystrophin
mRNA that would be translated into a protein that retains
some level of function and thereby reduce disease severity.
Exondys 51 is specifically designed to address the most
common sub-group of DMD mutations, selected genomic
deletions flanking exon 51, and will be relevant to ap-
proximately 13% of DMD deletion patients (Fig. 2). Boys
Fig. 1 Milestone timeline of the development and clinical use of antisense oligonucleotides
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that have been receiving Exondys 51 are remaining ambu-
lant and have reduced respiratory muscle decline when
compared to historical data [36]. Recent phase 1/2 clinical
trials with golodirsen developed to skip exon 53 in DMD
have shown a 10-fold increase in dystrophin protein ex-
pression in muscle samples after 48 weeks of treatment
[37], with phase 3 trials ongoing (NCT02500381).
Different DMD-causing mutations require other
splice-switching strategies to reframe the dystrophin
mRNA, and at least five additional compounds target-
ing exons 51, 53, 46, 50 and 43 would address up to
43% of DMD mutations [38]. To further increase the
spectrum of mutations that can be targeted, multiple
AOs could be combined as a cocktail to target blocks
of sequential exons [39]. In addition to the increased
range of mutations that can be targeted, successful
multiple exon skipping combinations can then be
applied to a broader pool of patients. This strategy has
been developed for several mutations in DMD but is
yet to be translated [39–41]. It has also been proposed
that skipping exons 45–55 of the DMD gene could
result in a functional protein isoform and rescue up to
63% of patients with DMD [42].
SMA is a fatal autosomal recessive neuromuscular disease
that results in progressive paralysis with muscular atrophy
in the first years of life [43]. Survival motor neuron (SMN)
1 and SMN2 genes encode the SMN protein, and although
both genes potentially code for identical proteins, a C>T
polymorphism in the third base of a glycine codon in exon
7 disrupts normal processing of SMN2, such that exon 7 is
omitted from the majority of the transcripts. SMA is caused
by the homozygous loss of the SMN1 gene and inability of
two copies of SMN2 to compensate protein production due
to inefficient splicing of exon 7 [44]. A splice-switching AO
was developed to target the SMN2 intronic splice silencer
element ISS-N1 and promote exon 7 inclusion, thereby
allowing SMN2 to produce the full-length and functional
SMA protein [45] (Fig. 3). In 2016, the splice-switching AO
therapeutic, nusinersen (SPINRAZA®), was approved by the
FDA [46]. Nusinersen is injected intrathecally in patients as
soon as a SMA diagnosis is confirmed. Nusinersen
increases full-length SMN protein levels in the spinal cord,
Fig. 2 Exondys 51™ excludes dystrophin exon 51 and corrects the DMD reading frame, therefore reducing disease severity in the most common
type of DMD mutation. a Normal splicing of DMD exons 49–52. b Exon 51 is deleted from the DMD transcript as the result of a mutation at affect
about 13% of DMD patients. Exondys 51 alters splicing of exon 51, removing it from the DMD transcript, restoring the reading frame and
reducing disease severity, reflecting a Becker MD phenotype
Fig. 3 SPINRAZA® strengthens exon 7 recognition and retention in the SMN2 mRNA transcript, reducing SMA disease severity. a Predominant
splicing of SMN2 exons 6–9. b An exonic polymorphism weakens exon 7 selection in the SMN2 mRNA. SPINRAZA® strengthens exon 7 selection
in the SMN2 transcript, producing a functional protein and reducing SMA disease severity
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therefore improving motor function in SMA patients and
presumably extending life expectancy [47].
Potential of antisense oligonucleotide therapy in CF
Cystic fibrosis (CF) is a life-threatening, autosomal
recessive genetic disease that affects multiple organs,
caused by mutations in the gene encoding the CF trans-
membrane conductance regulator (CFTR) protein. These
mutations result in either a complete lack or reduction
of protein or an incorrect functioning protein at the
apical surface of epithelial cells [48]. The predominant
clinical effects of CFTR mutations are progressive lung
disease and malnutrition. In the lungs, abnormal function
of chloride channels results in a dehydrated airway sur-
face. Poorly functioning mucociliary clearance leads to
chronic inflammation, infection and progressive destruc-
tion of lung tissue, followed by respiratory failure [49]. In
the pancreas, pancreatic duct obstruction results in failure
of pancreatic exocrine function, in particular the loss of
lipase activity, causing fat malabsorption. Whereas the
nutritional consequences of CFTR dysfunction can be
effectively treated by exogenous pancreas and diet, the
pulmonary consequences have proved less easy to treat.
Mutations have been identified in all CFTR exons and
introns [50], grouped into six classes of CFTR mutations
that have already been extensively reviewed [49, 51]. The
biological consequences of CFTR mutations are numer-
ous, and two main types of drugs have been investigated
to correct these effects: the potentiators and correctors
that increase ion flow (class III and IV mutations) and
enhance productive trafficking (class II mutations),
respectively [52, 53].
Over 2000 known mutations of CFTR causing CF have
been identified, but only four, in addition to the most
common p.Phe508del that accounts for over 70% of
mutations in Caucasians, have frequencies of greater
than 1–3%. Multiple drugs are being developed aiming
to improve the symptoms of CF including poor muco-
ciliary clearance, inflammation, infection and nutritional
deficits. Two approved drugs are currently available
to restore CFTR function: ivacaftor (Kalydeco®) and
lumacaftor + ivacaftor (Orkambi®). Ivacaftor has been
shown to improve the ability of the defective CFTR
channel to open, once on the apical surface of the
cell [53], and is approved for 33 different mutations.
Lumacaftor improves processing of the CFTR protein
and transport to the apical surface of the cell [54].
Lumacaftor has been combined with ivacaftor as
Orkambi® and is approved for patients homozygous
for the p.Phe508del mutation. A summary of CFTR
drugs that are currently in phase 2/3 clinical trials is
outlined in Table 2. A phase 3 trial of ataluren
(Translarna™), a small molecule developed to induce
“read-through” of nonsense mutations, commenced in
2015 but was terminated after it failed to improve
lung function over 48 weeks of treatment [55]. Of the
2000+ CFTR mutations identified, only 33 have an
approved and available corrective therapy.
A potential therapeutic strategy to reduce the CF
disease burden is to identify which of the ~ 2000 CF
mutations are amenable to AO-mediated splice inter-
vention. A study by Sterne-Weiler and colleagues
(2014) found that approximately 25% of all pathogenic
missense or nonsense mutations actually caused
abnormal splicing [4]. If such statistics were applic-
able to CFTR mutations, then up to 500 different
mutations may be amenable to AO splice-switching
as personalised therapies. Here, manipulation of gene
expression using AOs could be used to target specific
but less frequent CFTR mutations. In CF, nonsense,
splicing and frameshift mutations are known to occur
in all CFTR exons [50] and currently have no
Table 2 CFTR drugs in current phase 2 or 3 clinical trials
Name Clinical trial ID Co-treatment Phase Trial status Mutation Comments
GLPG2222 NCT03119649
NCT03045523
–
Ivacaftor
2
2
Recruiting
Recruiting
508/508
508/class III
Corrector
Cavosonstat (N91115) NCT02589236
NCT02724527
Orkambi
Ivacaftor
2
2
Complete
Ongoing, but not recruiting
508/508
508/class III
Increase levels of a signalling
molecule S-nitrosogluthione
(GSNO)
Tezacaftor (VX-661) NCT02392234
NCT03150719
NCT02951182
NCT02951195
Ivacaftor
Ivacaftor
Ivacaftor + VX-440
Ivacaftor + VX-152
3
3
2
2
Complete
Recruiting
Recruiting
Recruiting
508/RF
508/508
508/508; 508/MF
508/508; 508/MF
Move the defective CFTR
protein to the proper place
in the airway cell surface
CTP-656 NCT02971839 – 2 Recruiting Gating mutations Altered form of ivacaftor
Riociguat (BAY63-2521) NCT02170025 – 2 Recruiting 508/508 Stimulates soluble guanylyl
cyclases (sGC), an enzyme in
the cardiopulmonary system
QR-010 NCT02532764 – 1/2 Recruiting 508/508 RNA-based oligonucleotide
Data is correct as of 19/07/2017 from https://clinicaltrials.gov/ct2/home
MF minimal CFTR function mutation, RF residual CFTR function mutation, 508 p.Phe508del
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effective CFTR function-correcting treatment. AO
therapy could be used in specific CF cases to alter
splicing to skip an exon containing a nonsense or
frameshift mutation, restoring the reading frame, as-
suming the resultant isoform retained better function
than the mutated protein. Such a strategy could re-
store function to the resulting CFTR protein and re-
duce the severity of disease in amenable patients. In
2004, Zamecnik et al. constructed a modified oligo-
deoxyribonucleotide to restore CFTR function by
inserting into the mRNA the three missing bases
caused by the p.Phe508del CFTR mutation. The AO
had a central segment containing a phosphorothioate
modification and the adjoining segments phosphoro-
thioate plus 2′-O-methyl modifications [56]. This
modified AO was used in vitro and showed improved
CFTR function [56]. There is currently a phase 1/2
clinical trial ongoing using a modified RNA oligo-
nucleotide QR-010 that is designed for p.Phe508del
mutation and is based on the 2004 publication by
Zamecnik and colleagues [55].
In addition to exon skipping strategies, a proportion of
sequence variations and synonymous changes could
weaken splicing, compromising exon selection and
retention in the mature mRNA and thereby contribute to
disease severity. Deleterious alternative splicing of CFTR
exon 10, mediated by intronic polymorphisms, has been
reported as a cause of CF in a subset of patients [57–59].
AOs can be used to strengthen the retention of CFTR
exon 10 in the mature mRNA and could influence the
manifestation of the disease in patients with various muta-
tions, or used to complement alternative strategies by in-
creasing the mRNA levels (Fig. 4). An in vitro example is
for CFTR splicing mutation 2657+5G>A mutation that
causes exon 16 to be excluded during splicing; however,
the transcript was corrected by an AO designed to
strengthen exon 16 inclusion [60]. A mutation found in
5% of Ashkenazi Jewish patients, 3849 + 10 kb C→T,
creates a novel donor site in intron 19, causing an 84
base-pair pseudo-exon to be included in the mRNA and
generation of a premature stop codon [61–63]. In vitro
correction of this splicing defect using AOs was achieved
in 1999 by Friedman et al.; however, no clinical application
is yet available [62].
Antisense oligonucleotide therapy for the treatment of
disorders of surfactant protein metabolism
Pulmonary surfactant, produced by type II alveolar cells in
the alveoli, is critical to overcome surface tension at the air-
liquid interface and prevent alveolar collapse upon end
expiration [64]. Lamellar bodies, present in type II alveolar
cells, are the key subcellular organelles involved in surfac-
tant metabolism. Pathogenic mutations in genes involved in
surfactant production and homeostasis have been associ-
ated with neonatal respiratory distress in infants and diffuse
lung disease in children [65, 66]. Collectively, inherited con-
ditions caused by pathogenic mutations in the genes
encoding surfactant protein B (SFTPB), surfactant protein
C (SFTPC) and ATP-binding cassette subfamily A member
3 (ABCA3) are referred to as disorders of surfactant protein
metabolism (DSPM). Conditions associated with SFTPB
and ABCA3 mutations demonstrate autosomal recessive
inheritance, while SFTPC disorders are autosomal
dominant. Although rare, DSPM are associated with high
morbidity and mortality, with a spectrum of pathology/
phenotype that ranges from rapidly fatal in the neonatal
period to chronic lung disease that slowly resolves during
childhood [67]. Surviving patients require considerable
healthcare input in the first years of life and often require
extended stays in hospital. Age of disease onset, histopath-
ology of lung tissue, lamellar body ultrastructure and
clinical outcomes vary considerably according to the gene
affected and have been reviewed elsewhere [65, 66, 68].
No mechanism-specific interventions are currently
available to treat DSPM, and treatment options are
limited to supportive care, use of drugs that may confer
serious long-term side effects or lung transplantation to
prolong survival [69]. Clinical presentation of neonatal
respiratory insufficiency is similar to respiratory distress
syndrome of prematurity, yet treatment with exogenous
surfactant has been shown to have little benefit in
patients with DSPM [70]. Systemic corticosteroids are
Fig. 4 Deleterious alternative splicing of CFTR exon 10 could be addressed using splice-switching AOs. a Normal splicing of exons 9–11 of CFTR.
b An intronic polymorphism weakens exon 10 selection in CFTR mRNA. AO-mediated retention of CFTR exon 10 in the mature mRNA
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often prescribed empirically to treat diffuse lung disease
associated with ABCA3 or SFTPC mutations by immu-
nomodulation, but clinical trial data that demonstrates
efficacy of this therapeutic strategy is lacking at this
time. Some case reports do support the use of hydroxy-
chloroquine for patients presenting with diffuse lung dis-
ease [71], while other reports propose a combination of
intravenous pulse methylprednisolone and azithromycin
with hydroxychloroquine [72], but these treatment regi-
mens may only be beneficial in a subset of patients.
Moreover, concerns regarding the risks associated with
long-term use of antibiotics, corticosteroids [73] and
hydroxychloroquine [70] are well documented. There-
fore, there is a need to develop new therapeutics that
directly target the disease mechanism.
The use of AOs to treat disorders of surfactant protein
metabolism is one therapeutic approach that has yet to be
explored. A vast number of pathogenic mutations including
frameshifting indel, nonsense, missense and splice muta-
tions in surfactant-related genes have been identified to date
[65, 74]. Depending on the nature of the mutation, a range
of AO splice-correcting strategies could be exploited in an
attempt to restore protein function and attenuate disease.
AOs could sterically block aberrant splice sites to inhibit
abnormal splicing. A number of splice mutations in ABCA3
have been reported to date, such as c.1112-20 G>A, c.1742-
10 T>A, c.3862+4 A>T and IVS-98T (Fig. 5) [74, 75], that
may be amenable to AO therapy. Of the ABCA3 splice
mutations reported in the literature, the effects of specific
mutations on exon selection are not often described. While
splice mutations in the two invariant intronic bases flanking
each exon have also been reported (e.g. c.4909+1 G>A,
c.1612-2 A>G), these mutations are not amenable to splice
correction, since the canonical splice sites are lost. Alterna-
tively, for disease associated with loss of function of ABCA-
3, SP-B or SP-C proteins, AOs could be used to skip exons
containing frameshift or nonsense mutations to restore the
open reading frame.
The majority of disease-causing mutations in SFTPC
are found within the BRICHOS domain (exons 4 and 5)
of the SP-C pro-peptide, including the first reported
SFTPC mutation, c.460+1 G, which results in the skip-
ping of exon 4 due to loss of the canonical donor splice
site [76]. Mutations in the BRICHOS domain of SP-C
result in protein misfolding and cytosolic accumulation
of the aberrant protein, with a dominant negative effect
[77]. For disease linked to toxic gain-of-function associ-
ated with certain SFTPC mutations [78], AOs may po-
tentially be utilised to reduce levels of abnormal SP-C
proteins, if allele-specific silencing was possible.
Delivery of antisense oligonucleotide therapy
One of the major challenges in developing AO-based
therapeutics is to achieve efficient delivery to disease-
relevant tissue in vivo and, in addition, overcome the
cellular barriers that prevent AOs from reaching intra-
cellular molecular targets in the nucleus where splicing
takes place. Additionally, AO intervention only allows
for transient correction of aberrant gene expression or
splicing, making the development of appropriate dosing
and drug administration regimens paramount.
The route of drug administration is a significant factor
influencing the biodistribution of a particular AO.
Systemic administration by parental injection (either
intravenous infusion or intraperitoneal or subcutaneous
injection) typically results in the highest accumulation
levels of AO in the liver and kidney followed by the bone
marrow, adipocytes and lymph nodes [79]. Studies of
delivery via the inhalation route have been met with
mixed results: one study investigating the administration
of ‘naked’ AOs through the intratracheal route showed
little effect on local lung tissues while demonstrating an
accumulation of AO in the liver and kidney at levels
comparable to intravenous injection [80]. Other studies
have shown successful AO-mediated downregulation of
target protein expression in the lung [81, 82], demonstrating
Fig. 5 Splice mutation in ABCA3 causes partial intron 25 inclusion in the mRNA resulting in DSPM. a Normal splicing of ABCA3 exons 24–26. b
Aberrant splicing of intron 25 caused by point mutation, IVS-98T, introduces a stop codon after 77 additional amino acids after exon 25, resulting
in a truncated protein. AO-mediated splice correction could potentially reduce the disease severity
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the effective targeting of AOs to pulmonary tissue [68]. In
the context of AO therapy for asthmatic airway disease,
the aerosol delivery of AO has been trialled in preclinical
animal models targeting the interleukin 4 receptor α
[83, 84], interleukin 5 receptor α [85], p38 mitogen-
activated protein kinase [86] and CD86 [87]. In these
particular studies, AO-induced knockdown of molecular
targets resulted in reduction of airway hyper-responsiveness
and pulmonary inflammation.
Different strategies that may be employed to enhance
AO delivery also influence tissue distribution and
biological actions of AOs, compared to the delivery of
‘free’ oligonucleotides. These methods may include the
use of carrier molecules, conjugation and/or co-
administration with other factors. One such strategy is to
incorporate the AO into either a lipid [88, 89] or poly-
meric [90] nanocarrier to promote cellular uptake and
facilitate endosomal release. Lipid nanocarriers, for in vivo
use, have a surface coating (such as polyethylene glycol)
that reduces the recognition and uptake of the nanocarrier
by macrophages [91] while cationic lipids in the particle
enable AOs to escape from the endosome after endocyto-
sis into the target cell. However, toxicities attributed to the
effect of cationic lipids on cell membranes raise doubts
about the clinical use of lipid nanocarriers [92]. Typically,
both lipid and polymeric nanoparticles have limited bio-
distribution due to their relatively large size (~ 100 nm),
raising further concerns regarding toxicity [92].
Another strategy is to modify the AO by conjugation
to particular ligands such as lipids [93], carbohydrates,
peptides [94] or aptamers [95]. The biodistribution of
conjugated oligonucleotides is less restricted than those
complexed to nanocarriers, and the conjugates can easily
pass across the capillary endothelial barrier. Likewise,
the potential for toxicity seems to be lower than for
nanocarriers [90]. Conjugated oligonucleotides also have
the potential for selective targeting to a wide range of
specific tissue receptors such as integrins, toll-like
receptors or receptor tyrosine kinases [92]. Conjugation
with N-acetylgalactosamine has been widely used to en-
hance delivery of oligonucleotides to hepatocytes [15].
However, unlike nanocarriers, conjugates are subject to
rapid renal clearance due to their small size, limiting
their bioavailability.
Delivery efficiency may also be improved through the
co-administration of particular factors with the AO. In a
study in mice, AO-induced transgene expression was
improved when a specific 2′-O-methyl RNA was injected
intramuscularly together with a non-ionic block copoly-
mer, F127 [96]. Additionally, studies in the DMD mdx
mouse model demonstrate that cellular uptake of a PMO
is enhanced by co-administration of a glucose-fructose
formulation, resulting in the restoration of higher dys-
trophin protein levels in the skeletal muscle [97].
Not only does an AO’s therapeutic effect depend on
reaching the target cell, the AO must also reach intracel-
lular molecular targets. Internalisation of AOs at the cell
surface can occur through multiple pathways and may
depend on the cell type and the cell’s physiological state
[98]. However, endocytosis of the AO does not guaran-
tee delivery to intracellular target sites as they must first
escape from membrane-bound intracellular compart-
ments [92]. Endosome contents, including internalised
AOs, are largely directed to lysosomes for degradation
or to the plasma membrane for expulsion to the cell
exterior where they are unable to fulfil their therapeutic
function. It is widely regarded that the endosomal escape
barrier is one of the most significant obstacles to the
effective use of AOs in therapeutics [92].
Conclusions
Although rare in the paediatric population, lung disease
associated with genetic conditions results in significant
patient morbidity and mortality. Current therapies may
benefit subsets of patients, but there is a need to generate
new treatment strategies for specific patient populations.
While AO therapy is an area yet to be explored in CF or
DSPM, AOs offer potential strategies to develop targeted
personalised treatments for people with specific gene
mutations. Challenges remain with respect to clinical trial
design in this area, due to limited cohorts of patients from
which to draw participants, further compounded by strati-
fication according to individual mutations [8, 9]. Further-
more, the variability in the natural history of disease
between patients is significant, making the application of
standardised outcome measures and selection of clinical
endpoints difficult. One advantage of any hypothesis-
driven translational research that aims to alter targeted
gene expression is the ability to undertake molecular
analyses that confirm changes in mRNA transcripts
(reverse transcriptase PCR) or protein levels (western blot-
ting, immunohistochemical staining or functional testing).
If no changes in the RNA or protein were detected, one
would not expect to see any clinical improvements.
Conversely, even low changes in the RNA and induced
protein have conferred substantial clinical benefits in
DMD, indicating that even modest levels of functional
protein can confer a therapeutic benefit. Ultimately, the
investigation into relevant molecular targets, prospective
AO drugs and appropriate in vivo drug delivery systems
will prove vital to determine the clinical potential of this
therapy to treat lung diseases of genetic origin.
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